Table 1.

Clinical and pathologic characteristics of patients treated with PD-1/PD-L1 inhibitors

CharacteristicEGFR-mutant or ALK-positive (N = 28)EGFR WT & ALK-negative/unknown (N = 30)P
Age at diagnosis
 Median54.564.50.005
 Range36–7535–77
Sex, n (%)
 Male8 (29)18 (60)0.020
 Female20 (71)12 (40)
Ethnicity, n (%)
 Caucasian22 (79)28 (93)0.292
 Asian4 (14)2 (7)
 Othera1 (4)0 (0)
Smoking history, n (%)
 Never16 (57)1 (3)<0.001
 Light (≤10 pack years)6 (21)1 (3)
 Heavy (>10 pack years)6 (21)28 (93)
Histology, n (%)
 Adenocarcinoma27 (96)21 (70)0.018
 Squamous1 (4)8 (27)
 Other0 (0)1 (3)b
Molecular genotype, n (%)
 EGFR mutations22 (79)0 (0)<0.001
 ALK rearrangements6 (21)0 (0)
 KRAS mutations0 (0)11 (37)
 Other/unknownc0 (0)19 (63)
Prior lines of therapy
 Median320.008
 Range0–80–4
Prior tyrosine kinase
 Inhibitor, n (%)23 (82)5 (17)<0.001
PD-1 vs. PD-L1 inhibitors, n (%)
 PD-1 inhibitors23 (82)20 (67)0.235
  - Nivolumab9 (32)4 (13)
  - Pembrolizumab14 (50)16 (53)
 PD-L1 inhibitors5 (18)10 (33)
  - Durvalumab3 (11)1 (3)
  - Atezolizumab1 (4)9 (30)
  - Other1 (4)0 (0)
  • aNot available in one patient.

  • bDenotes a patient with adenosquamous histology.

  • cSix patients with squamous histology did not undergo ALK testing.

  • dPercentages may not add up to 100 due to rounding.